Alkem Laboratories Future Growth
Future criteria checks 1/6
Alkem Laboratories is forecast to grow earnings and revenue by 17.5% and 9.7% per annum respectively. EPS is expected to grow by 19% per annum. Return on equity is forecast to be 18.7% in 3 years.
Key information
17.5%
Earnings growth rate
19.0%
EPS growth rate
| Pharmaceuticals earnings growth | 18.8% |
| Revenue growth rate | 9.7% |
| Future return on equity | 18.7% |
| Analyst coverage | Good |
| Last updated | 19 Apr 2024 |
Recent future growth updates
Recent updates
Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13
Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease
Dec 27Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 14Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Aug 02Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Jul 07Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
May 22We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt
Mar 27Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Dec 26These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well
Sep 20Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00
Jul 27Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 13Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jun 11Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
May 23Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Mar 06Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
Feb 21Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year
Feb 08Should You Be Adding Alkem Laboratories (NSE:ALKEM) To Your Watchlist Today?
Jan 09Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Nov 30Here's Why Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt Responsibly
Nov 17I Built A List Of Growing Companies And Alkem Laboratories (NSE:ALKEM) Made The Cut
Sep 07Here's Why Alkem Laboratories Limited's (NSE:ALKEM) CEO May Deserve A Raise
Aug 20Alkem Laboratories (NSE:ALKEM) Is Increasing Its Dividend To ₹5.00
Aug 03Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Jul 19Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?
Jul 01Do Alkem Laboratories's (NSE:ALKEM) Earnings Warrant Your Attention?
May 25What Kind Of Investors Own Most Of Alkem Laboratories Limited (NSE:ALKEM)?
Mar 17Why Dividend Hunters Love Alkem Laboratories Limited (NSE:ALKEM)
Mar 04Alkem Laboratories Limited (NSE:ALKEM) Insiders Have Been Selling
Feb 19Do Alkem Laboratories's (NSE:ALKEM) Earnings Warrant Your Attention?
Feb 07Alkem Laboratories (NSE:ALKEM) Could Be A Buy For Its Upcoming Dividend
Feb 07Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2026 | 156,391 | 25,081 | 18,411 | N/A | 15 |
| 3/31/2025 | 142,146 | 21,700 | 15,632 | N/A | 16 |
| 3/31/2024 | 129,136 | 18,672 | 13,158 | N/A | 16 |
| 12/31/2023 | 126,344 | 15,732 | N/A | N/A | N/A |
| 9/30/2023 | 123,514 | 14,329 | 18,370 | 20,537 | N/A |
| 6/30/2023 | 119,906 | 11,433 | N/A | N/A | N/A |
| 3/31/2023 | 115,993 | 9,842 | 14,496 | 16,825 | N/A |
| 12/31/2022 | 111,805 | 10,208 | N/A | N/A | N/A |
| 9/30/2022 | 107,586 | 10,917 | 5,527 | 8,426 | N/A |
| 6/30/2022 | 104,792 | 13,051 | N/A | N/A | N/A |
| 3/31/2022 | 106,342 | 16,456 | 7,721 | 11,110 | N/A |
| 12/31/2021 | 103,425 | 17,780 | N/A | N/A | N/A |
| 9/30/2021 | 100,416 | 17,033 | 10,478 | 13,213 | N/A |
| 6/30/2021 | 96,044 | 16,311 | N/A | N/A | N/A |
| 3/31/2021 | 88,650 | 15,850 | 11,051 | 12,649 | N/A |
| 12/31/2020 | 87,218 | 15,338 | N/A | N/A | N/A |
| 9/30/2020 | 85,971 | 14,648 | 8,916 | 11,455 | N/A |
| 6/30/2020 | 84,984 | 13,636 | N/A | N/A | N/A |
| 3/31/2020 | 83,444 | 11,271 | 2,220 | 5,851 | N/A |
| 12/31/2019 | 81,484 | 11,057 | N/A | N/A | N/A |
| 9/30/2019 | 78,929 | 9,262 | 5,173 | 8,756 | N/A |
| 6/30/2019 | 75,478 | 8,098 | N/A | N/A | N/A |
| 3/31/2019 | 73,572 | 7,605 | 2,505 | 7,797 | N/A |
| 12/31/2018 | 70,157 | 6,602 | N/A | N/A | N/A |
| 9/30/2018 | 68,318 | 6,293 | N/A | N/A | N/A |
| 6/30/2018 | 67,788 | 6,955 | N/A | N/A | N/A |
| 3/31/2018 | 63,918 | 6,309 | -4,177 | 2,660 | N/A |
| 12/31/2017 | 60,044 | 7,009 | N/A | N/A | N/A |
| 9/30/2017 | 57,285 | 7,626 | N/A | N/A | N/A |
| 6/30/2017 | 55,019 | 7,248 | N/A | N/A | N/A |
| 3/31/2017 | 56,875 | 8,920 | N/A | 4,711 | N/A |
| 12/31/2016 | 56,933 | 7,732 | N/A | N/A | N/A |
| 9/30/2016 | 54,992 | 7,267 | N/A | N/A | N/A |
| 6/30/2016 | 52,419 | 7,108 | N/A | N/A | N/A |
| 3/31/2016 | 49,248 | 7,416 | N/A | 7,258 | N/A |
| 12/31/2015 | 47,975 | 8,189 | N/A | N/A | N/A |
| 9/30/2015 | 44,556 | 7,227 | N/A | 4,023 | N/A |
| 6/30/2015 | 40,459 | 5,781 | N/A | N/A | N/A |
| 3/31/2015 | 37,434 | 3,916 | N/A | 3,255 | N/A |
| 3/31/2014 | 31,191 | 4,353 | N/A | 2,900 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALKEM's forecast earnings growth (17.5% per year) is above the savings rate (6.7%).
Earnings vs Market: ALKEM's earnings (17.5% per year) are forecast to grow slower than the Indian market (17.6% per year).
High Growth Earnings: ALKEM's earnings are forecast to grow, but not significantly.
Revenue vs Market: ALKEM's revenue (9.7% per year) is forecast to grow slower than the Indian market (10% per year).
High Growth Revenue: ALKEM's revenue (9.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALKEM's Return on Equity is forecast to be low in 3 years time (18.7%).